Home Cart Sign in  
Chemical Structure| 353519-63-8 Chemical Structure| 353519-63-8

Structure of HLM006474
CAS No.: 353519-63-8

Chemical Structure| 353519-63-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

HLM006474 is a potent inhibitor of melanocytes proliferation and subsequent invasion in a three-dimensional tissue culture model system and interferes with E2F activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of HLM006474

CAS No. :353519-63-8
Formula : C25H25N3O2
M.W : 399.48
SMILES Code : OC1=C2N=C(C)C=CC2=CC=C1C(C3=CC=C(OCC)C(C)=C3)NC4=NC=CC=C4
MDL No. :MFCD02168344
InChI Key :CYNZBLNMIJNBSF-UHFFFAOYSA-N
Pubchem ID :2895500

Safety of HLM006474

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H413
Precautionary Statements:P301+P312+P330

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HCC xenograft model Intraperitoneal injection 20 mg/kg Tumor volumes were monitored weekly for 6 weeks Validate the inhibitory effects of HLM6474 and SIS3 on HCC growth in vivo Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6103-6113
Mice EcKO Sox17 mice Intraperitoneal injection 12.5 mg/kg 3 times a week for 6 weeks To evaluate the effect of E2F1 inhibitor HLM006474 on the development of pulmonary hypertension in ecKO Sox17 mice, results showed that HLM006474 significantly attenuated the development of pulmonary hypertension. Hypertension. 2023 Nov;80(11):2357-2371

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.50mL

0.50mL

0.25mL

12.52mL

2.50mL

1.25mL

25.03mL

5.01mL

2.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories